Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond

(MedPage Today) -- MADRID -- Patients with previously treated small-cell lung cancer (SCLC) obtained durable responses with either of two doses of the bispecific T cell-engaging (BiTE) antibody tarlatamab, according to a study reported here....
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news